Drug Profile
Olmesartan ophthalmic
Alternative Names: CS 088; DE 092; Ophthalmic olmesartan - SantenLatest Information Update: 25 Mar 2009
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Santen Pharmaceutical
- Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 05 Nov 2008 Discontinued - Phase-II for Glaucoma in European Union (Ophthalmic)
- 05 Nov 2008 Discontinued - Phase-II for Glaucoma in Japan (Ophthalmic)
- 05 Nov 2008 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)